Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03768817 · ClinicalTrials.gov registry record
Clinical Outcome of Triheptanoin Treatment in Patients With Long-chain Fatty Acid Oxidation Disorders (LC-FAOD) Treated Under Expanded Access Program
A clinical trial of Long-chain Fatty Acid Oxidation Disorders (LC-FAOD), sponsored by Ultragenyx Pharmaceutical.
- Completed
- Registry status
- 20
- Enrollment target
- 15
- Study locations
NCT03768817: Completed study of Long-chain Fatty Acid Oxidation Disorders (LC-FAOD), sponsored by Ultragenyx Pharmaceutical.
NCT03768817 is a study of Long-chain Fatty Acid Oxidation Disorders (LC-FAOD) that has completed, run by Ultragenyx Pharmaceutical. The registered enrollment target is 20 participants. The trial reports 15 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03768817, a study of Long-chain Fatty Acid Oxidation Disorders (LC-FAOD), has completed, sponsored by Ultragenyx Pharmaceutical.
- COMPLETED
- Registry status
- 20 participants
- Enrollment target
- 15
- Study locations
Study Summary
The primary objective of the study is to evaluate the clinical outcomes for the trigger event of patients who receive triheptanoin in the emergency Investigational New Drug (eIND) program.
Conditions Studied
Interventions
- OTHER No Intervention
Study Locations (15)
California
- Children's Hospital of Los Angeles - Los Angeles
- Kaiser Permanente - Los Angeles
- Children's Hospital of Orange County - Orange
- Stanford University - Palo Alto
Pennsylvania
- Children's Hospital of Philadelphia - Philadelphia
- UPMC Children's Hospital of Pittsburgh - Pittsburgh
Connecticut
- Yale University - New Haven
District of Columbia
- Children's National Hospital - Washington D.C.
Florida
- University of South Florida - Tampa
Georgia
- Emory University - Atlanta
Massachusetts
- Boston Children's Hospital - Boston
Minnesota
- University of Minnesota Masonic Children's Hospital - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2019-01-30 |
| Est. Completion | 2020-06-08 |
What the finished NCT03768817 record still lists
NCT03768817 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 20 participants, a relatively small participant target.
The record links to 1 condition, with Long-chain Fatty Acid Oxidation Disorders (LC-FAOD) appearing as the primary indexed condition, and to 1 intervention - of which No Intervention is the first listed.
NCT03768817 lists 15 locations in 11 states (California, Pennsylvania, Connecticut).
Frequently Asked Questions
What is clinical trial NCT03768817 about?
NCT03768817 is a clinical study titled "Clinical Outcome of Triheptanoin Treatment in Patients With Long-chain Fatty Acid Oxidation Disorders (LC-FAOD) Treated Under Expanded Access Program". The primary objective of the study is to evaluate the clinical outcomes for the trigger event of patients who receive triheptanoin in the emergency Investigational New Drug (eIND) program.
What is the current status of trial NCT03768817?
This trial is currently completed. The enrollment target is 20 participants. The study started on 2019-01-30. Estimated completion is 2020-06-08.
What conditions does trial NCT03768817 study?
This clinical trial studies the following conditions: Long-chain Fatty Acid Oxidation Disorders (LC-FAOD).
What interventions are being tested in trial NCT03768817?
The interventions under investigation include: No Intervention (OTHER).
Who is sponsoring clinical trial NCT03768817?
This trial is sponsored by Ultragenyx Pharmaceutical, which has 52 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03768817 being conducted?
This trial has 15 study locations across California, Connecticut, District of Columbia, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI